JOJ
Urology & Nephrology
ISSN: 2476-0552

Review Article
Volume 9 Issue 1 - May 2024
DOI: 10.19080/JOJUN.2024.08.555751

JOJ uro & nephron

Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis

José C Rosario Curcio[1], Tania Elizabeth Salvador[2], Alba Vidal Ronchas[1], Carlos E Díaz Ortiz[1], Nune Azaryan Dermenjian[3], Vianka Vanessa Yánez Montalvo[4], Melanie Dayana Yánez Montalvo[4], Marcela Garzon[5], Fátima Melissa Morales Navarro[6], Elizabeth Alfaro Pereira[7], Angela Juliet Torijano Sarria[8] and Maria Isabel Gomez Coral[9]*

[1]*University of Medicine and Health Sciences, St. Kitts*

[2]*Universidad de El Salvador, El Salvador*

[3]*Yerevan State Medical University, USA*

[4]*University of Guayaquil, Ecuador*

[5]*Universidad de Los Andes, Colombia*

[6]*Hospital Médico Quirúrgico ISSS, El Salvador*

[7]*Universidad Nacional de El Salvador*

[8]*Universidad Santiago de Cali, Colombia*

[9]*Universidad del Valle de México, México*

Submission: April 22, 2024; **Published:** May 02, 2024

***Corresponding author:** Maria Isabel Gomez Coral, Department of Medicine, Universidad del Valle de, Mexico

Abstract

Renal Tubular Acidosis (RTA) is a complex renal disorder characterized by impaired acid-base regulation, leading to metabolic acidosis. While traditionally classified into several subtypes based on renal tubular dysfunction, emerging evidence highlights the systemic implications of RTA beyond nephron physiology. This article explores the multifaceted systemic manifestations of RTA, including cardiovascular, endocrine, neurological, and psychosocial implications, and discusses the importance of recognizing and addressing these systemic effects in patient care. Through interdisciplinary collaboration and personalized medicine approaches, tailored therapeutic strategies can be developed to mitigate renal and extrarenal manifestations of RTA, thereby improving overall patient well-being. Furthermore, future research directions aimed at elucidating the intricate interplay between acid-base disturbances and systemic organ systems hold promise for advancing our understanding and management of RTA, ultimately enhancing patient care outcomes.

Keywords: Renal Tubular Acidosis; Systemic Implications; Acid-Base Disturbances; Cardiovascular Consequences; Endocrine Dysregulation; Metabolic Complications; Neurological Effects; Cognitive Impairment

Abbreviations: RTA: Renal Tubular Acidosis; HCO3: Bicarbonate; K+: Potassium; DEXA: Dual-Energy X-ray Absorptiometry; PCT: Proximal Convoluted Tubule; RANKL: Receptor Activator of Nuclear Factor Kappa B Ligand; AG: Anion Gap; SPS: Sodium polystyrene sulfonate; HPP: Hypokalemic Periodic Paralysis; PCO2: Partial pressure of carbon dioxide; CO2: Carbon dioxide; NH4+: Ammonium ion; DCT: Distal Convoluted Tubule; HCO3: Bicarbonate; Ca2+: Calcium ion; PTH: Parathyroid Hormone; DKA: Diabetic Ketoacidosis; ICU: Intensive Care Unit; AG: Anion Gap; ECF: Extracellular Fluid; CNS: Central Nervous System; PNS: Peripheral Nervous System; H+: Hydrogen ion; SPS: Sodium Polystyrene Sulfonate; ACE: Angiotensin-Converting Enzyme; ARBs: Angiotensin II Receptor Blockers

Introduction

Renal Tubular Acidosis (RTA) is a complex renal disorder characterized by impaired acid-base regulation, leading to metabolic acidosis. Classically classified into several subtypes, including Type 1, Type 2, and Type 4, RTA manifests through distinct mechanisms affecting renal tubular function. Type 1 RTA, or distal RTA, primarily stems from impaired hydrogen ion secretion in the distal nephron. In contrast, Type 2 RTA, known as proximal RTA, arises from defective bicarbonate reabsorption in the proximal tubule. Additionally, Type 4 RTA involves impaired renal ammonia genesis and aldosterone deficiency or resistance, reducing net acid excretion. These classifications underscore the intricate pathophysiology of RTA, elucidating diverse etiologies and clinical presentations that necessitate tailored therapeutic approaches [1,2]. Beyond its traditional characterization as a renal disorder, emerging evidence sheds light on the systemic implications of RTA, extending beyond the confines of nephron physiology. The intricate interplay between acid-based homeostasis and various organ systems underscores the multifaceted nature of RTA's impact. Complications such as bone demineralization, growth retardation, and electrolyte disturbances underscore the systemic ramifications of chronic acidosis. Furthermore, recent research suggests potential links between RTA and cardiovascular morbidity, highlighting the importance of comprehensive management strategies to mitigate both renal and extrarenal manifestations of this intricate disorder [1-4].

Types of RTA, Pathogenesis, Manifestations and Diagnosis

Distal RTA (type I) is characterized by impaired urinary acid secretion and evidence of kidney potassium (K_+) wasting with persistent alkaline urine pH. Patients often present with polydipsia, polyuria, and muscle weakness, as well as nephrolithiasis and nephrocalcinosis. Failure to thrive, growth retardation, and rickets is a joint presentation in children as a primary genetic defect [5,6]. Proximal (type 2) RTA is characterized by defects in the reabsorption of filtered HCO_{3-} in the proximal tubule [5]. It is usually associated with Fanconi syndrome, a generalized tubular dysfunction [6]. Symptoms include muscle weakness or paralysis (if severely hypokalemic) and growth retardation in early childhood [5]. Type 3 RTA is rare and has features of both distal and proximal RTA [5]. It manifests with debilitating congenital syndromes in children and is principally associated with carbonic anhydrase II deficiency [6]. Hyperkalemic (type 4) RTA is characterized by a reduction in the excretion of H+ and K+ in the cortical collecting duct. It is commonly associated with diabetes, interstitial nephritis, and medications, and it is related to aldosterone deficiency or resistance [5,6]. Patients are often asymptomatic, but manifestations may include muscle weakness or palpitations due to cardiac arrhythmia [5]. All types of RTA present with persistent hyperchloremic metabolic acidosis, but they have some key distinguishing features. Patients with distal RTA typically develop hypokalemia with a urine pH > 5.3. Proximal RTA may be suspected in patients with hypokalemia and acidic urine (pH < 5.5). An HCO3-loading test makes a definitive diagnosis for proximal RTA, and an NH4+ loading test for distal RTA to differentiate between them. Type IV results in hyperkalemia [5].

Acid-Base Homeostasis: A Systemic Perspective

Acid-based homeostasis is the maintenance of systemic pH within a narrow range. The systemic pH varies in response to respiratory or renal impairment in clinical and experimental settings [7]. The pulmonary system adjusts pH by utilizing carbon dioxide. Carbon dioxide is released into the environment during expiration. When the respiratory system compensates for metabolic pH disturbances, the effect occurs in minutes to hours [7-10]. These pH alterations induce vascular smooth muscle tone changes, impacting circulation and blood pressure control. Extracellular and intracellular pH changes influence each other. The pH has significant effects on the blood flow of several vascular beds. It is still under investigation whether intracellular or extracellular pH changes are responsible for vessel tone alteration arising from hypercapnic acidosis [7]. Celotto et al. discussed the recent discovery of nitric oxide in vasodilator responses to hypercapnia [7]. Following the increases or decreases in CO_2 production, alveolar ventilation increases or decreases to maintain PCO_2 and keep pH in the normal range [8,10]. The cells in the medulla and those in carotid bodies control the alveolar ventilation in response to changes in pH and pCO_2. Increases in plasma CO_2 decrease pH, increase ventilation drive, and return pCO_2 to its normal range [9,10]. The respiratory system can adjust the pH to a normal range within minutes to hours [10].

Renal tubular acidosis (RTA) is a group of renal tubular disorders. These pathologies are characterized by the inability to excrete H_+ in the urine. The high amounts of remaining H_+ ions cause metabolic acidosis. The net acid excretion by kidneys is decreased. In some cases, the urine pH cannot decrease below 5.5. Severe acidosis that arises from RTA does not impact the anion gap (AG), as the decrease in serum[HCO_{3-}] is addressed by a proportionate increase in serum [Cl-] [11]. Alkali therapy can help compensate for renal tubular acidosis (RTA) by lowering blood acid levels. This compensation with therapy prevents the occurrence of kidney stones. The preferred form of alkali therapy is potassium citrate. It is given in the amount that can buffer the daily acid load [12]. Clinical and laboratory evaluation is essential for appropriately diagnosing and managing RTAs.

Bone Health in RTA

Renal tubular acidosis (RTA) causes a state of chronic metabolic acidosis, which induces increased activity of osteoclasts and inhibits osteoblasts, leading to decreased bone formation by decreasing the expression of matrix proteins and alkaline phosphatase activity [13-15]. Simultaneously, prostaglandins produced by the osteoblasts, in response to acidity, increase the synthesis of the osteoblastic receptor activator of nuclear factor kappa B ligand (RANKL). RANKL then stimulates osteoclastic activity to promote bone resorption and buffering of protons [15]. In addition to the effects of chronic metabolic acidosis, in

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751

distal RTA, the renal tubules cannot reabsorb calcium, leading to hypocalcemia and associated secondary hyperparathyroidism. Hyperparathyroidism leads to increased mobilization of calcium and phosphorous from bone, leading to osteoporosis, osteomalacia, or Rickets, which can lead to bone pain, fragility, and fractures [14]. Mixed RTA, type III RTA, is associated with Guibaud-Vainsel Syndrome (autosomal recessive bone sclerosis), which also presents fractures, osteosclerosis, short stature, visual defects caused by optic nerve compression, dental occlusion errors, and basal ganglia calcification [14].

A dual-energy X-ray absorptiometry (DEXA) scan is recommended every 2-3 years to assess fracture risk and treatment adequacy to manage adult RTA-associated bone disease. In contrast, routine bone mineralization assessment is not recommended in children. In adults with distal RTA, T-score values and bone formation rates were significantly lower than in the general population; conversely, osteoid volume and surface were higher [16]. Oral alkali therapy is used to treat RTA-associated bone disease. The joint agents include citrate (e.g., Potassium citrate and citric acid mixture) and bicarbonate. The dose of the alkalizing therapy should be high enough to compensate for the HCO_{3-} lost in the urine and for the acid produced by dietary protein breakdown. Despite this, care should be taken to avoid acidosis overcorrection since it can lead to an increased urinary excretion of calcium and its associated complications [13].

Electrolyte Disturbances

In type 1 RAT, there is damage to the distal tubule, in which the alpha-intercalated cells are unable to secrete H_+, causing metabolic acidosis; this promotes K+ to be exchanged for Sodium, leading to hypokalemia. This hypokalemia worsens as the body tries to balance the metabolic acidosis by the $K_{+-}H_+$ pump, pushing K_+ intracellularly. To counterbalance this metabolic acidosis, chloride is increased in the serum. In RAT type 1, the inability to acidify the urine leads to bone demineralization and hypercalciuria, with risks for nephrolithiasis and hypocalcemia due to decreased intestinal absorption. In type 2 RTA, there is damage to the proximal convoluted tubules, impeding the reabsorption of bicarbonate, which leads to metabolic acidosis. The body secretes ammonia and exchanges potassium for H_+ ions to compensate for this loss, leading to hypokalemia [17].

Similarly to RTA type 1, there is hypercalciuria due to increased demineralization and hypocalcemia due to decreased intestinal absorption. Because magnesium is highly absorbed in the PCT, hypomagnesemia is associated with RTA type 2, with subsequent hypocalcemia due to the loss of magnesium. The most common RTA, which is type 4, is aldosterone resistance or deficiency in the DCT or collecting tube, leading to decreased potassium reabsorption. Because the acidosis is caused by aldosterone, either deficiency or resistance, the metabolic acidosis is usually milder than RTA 1 or 2, which does not lead to demineralization of the bones [18]. In mixed RTA, there are features of both Type 1 and Type 2 RT; this means that there is hypokalemia due to the absence of excretion of H_+ ions in the distal tubule and impaired reabsorption of bicarbonate, which further decreases the hypokalemia. The features of Type 1 RTA in mixed RTA promote bone mineralization, leading to hypocalcemia and hypercalciuria. This is also true about magnesium, as it can be lost due to damage to the PCT in Type 2 RTA.

In RTA, the primary electrolyte disturbances are potassium, magnesium, and calcium; each affected in different ways, as described above. Hypokalemia is one common disturbance that can lead to neuromuscular symptoms like muscle weakness, cramps, and fatigue; hypokalemia is also a common risk for developing arrhythmias, as potassium affects the membrane potential in cardiac cells. One rare disorder associated with hypokalemia in RTA is Hypokalemic Periodic Paralysis (HPP); this disorder is characterized by episodic muscle weakness that can lead to periodic paralysis, hypo or areflexia, and myopathy [19]. Calcium is another electrolyte affected in RTA, which is hyper-excreted in the kidneys and leads to hypocalcemia. Hypocalcemia can present as tetany, muscle spasms, involuntary muscle contraction, and QT prolongation, leading to arrhythmias. Magnesium is affected mainly in Type 2, where it is decreased, as explained before, leading to symptoms similar to hypocalcemia, such as tremors, muscle cramps, and tetany; however, hypomagnesemia can lead to torsades de pointes, which has been documented when combined with hypokalemia [20].

The management of RTA depends on the type, as each has its defect, even though electrolyte disturbances might be similar. For Type 1, the impairment can be corrected with alkali therapy 1-2 mmol/kg/day with sodium bicarbonate or potassium bicarbonate, which is sufficient to equal daily acid production; alkali therapy corrects hypokalemia but in patients with severe hypokalemia should also receive K_+ replacement [21]. For Type 2, the alkali therapy requirements are higher, as usual therapy is 10-15 mmol/kg/day with potassium replacement. Patients with type two are also treated with volume resuscitation to avoid dehydration, as well as calcium and vitamin D supplementation to avoid bone disease. In patients with Type 4, as the issue is in aldosterone deficiency or resistance, the treatment lies in the etiology in addition to diuretics. The loop and thiazide diuretics are a good option for type 4 RTA, as a critical feature is losing K+. Sodium bicarbonate (650 mg) is another pharmacologic therapy, which usually corrects acidosis and increases urinary K_+ excretion. Fludrocortisone is a third-line agent for RTA Type 4 as it is used as an aldosterone analog; this medication can exacerbate hypertension and fluid overload, so proper follow-up is needed. To control K+, Sodium polystyrene sulfonate (SPS) can be administered for Type 4 RTA. SPS is an exchange resin that promotes K_+ excretion through the colon, bypassing the kidneys. This medication can be viewed as a long-term medication for

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751

Type 4 RTA in patients with other K_+ losing treatments that have failed for different reasons; however, it cannot be used in patients with ileostomy or other intestinal surgeries [22]. Sodium citrate (Shohl's solution) has decreased the risk of nephrolithiasis in RTA with hypercalciuria.

Cardiovascular Consequences

Chronic metabolic acidosis, a hallmark of renal tubular acidosis (RTA), exerts profound cardiovascular implications, extending beyond the renal system. Prolonged acidemia induces a cascade of cardiovascular manifestations, including cardiac contractility, arrhythmogenesis, and vascular tone alterations. Acidosis directly impacts myocardial function, impairing cardiac contractility through alterations in intracellular calcium handling and myocardial energetics. Moreover, acidosis disrupts the electrophysiological properties of cardiac cells, predisposing RTA patients to arrhythmias, including ventricular tachycardia and fibrillation. Additionally, acidemia promotes vasoconstriction and endothelial dysfunction, contributing to elevated systemic vascular resistance and hypertension, further exacerbating the cardiovascular burden in RTA individuals [23-25]. The intricate interplay between acid-base disturbances and cardiovascular pathophysiology underscores the importance of tailored therapeutic interventions to mitigate cardiovascular risk in RTA patients. Correction of acidosis through alkali supplementation is a cornerstone in managing cardiovascular complications associated with RTA. Alkali therapy restores acid-base balance, ameliorating myocardial dysfunction, reducing arrhythmogenicity, and improving vascular endothelial function. Optimizing blood pressure control through antihypertensive agents, such as renin-angiotensin-aldosterone system inhibitors, further attenuates cardiovascular risk in RTA individuals. Moreover, dietary modifications, including sodium restriction and potassium supplementation, are crucial in managing hypertension and electrolyte disturbances, optimizing cardiovascular outcomes in RTA patients [24-26].

In conclusion, renal tubular acidosis transcends its traditional renal-centric paradigm, exerting profound cardiovascular consequences. Chronic metabolic acidosis in RTA individuals precipitates cardiac dysfunction, arrhythmias, and vascular abnormalities, necessitating comprehensive management strategies to mitigate cardiovascular risk. Alkali therapy, blood pressure optimization, and dietary interventions are pivotal therapeutic modalities in attenuating cardiovascular burden and improving outcomes in RTA patients [23-26].

Endocrine and Metabolic Dysregulation

Renal tubular acidosis (RTA) imposes significant disruptions upon the endocrine system, contributing to insulin sensitivity and cortisol metabolism alterations. Chronic metabolic acidosis, characteristic of RTA, induces insulin resistance by impairing insulin-mediated glucose uptake and utilization in peripheral tissues. Furthermore, acidosis stimulates hepatic gluconeogenesis, exacerbating hyperglycemia and promoting insulin resistance. These metabolic derangements not only heighten the risk of diabetes mellitus but also contribute to dyslipidemia and increased cardiovascular morbidity in RTA individuals. Moreover, acidosis alters cortisol metabolism, promoting cortisol synthesis and activation, which may exacerbate hypertension and metabolic disturbances in RTA patients [27]. The metabolic consequences of chronic acid-base disturbances in RTA extend beyond glucose homeostasis, encompassing bone metabolism and protein catabolism alterations. Acidosis elicits bone demineralization through enhanced bone resorption and impaired mineralization, predisposing RTA individuals to osteopenia, osteoporosis, and fractures. Furthermore, acidemia promotes muscle protein breakdown, exacerbating muscle wasting and weakness in RTA patients. These metabolic perturbations not only compromise musculoskeletal health but also contribute to growth retardation and impaired physical function in affected individuals [28-30]. A multifaceted approach encompassing pharmacological and dietary interventions is warranted to manage metabolic complications in RTA patients effectively. Alkali supplementation is a cornerstone in correcting metabolic acidosis, mitigating insulin resistance, and preserving bone health in RTA individuals. Additionally, dietary modifications, including adequate calcium and vitamin D intake, are crucial in optimizing bone metabolism and preventing skeletal complications in RTA patients. Moreover, judicious management of comorbidities, such as diabetes mellitus and hypertension, through lifestyle interventions and pharmacotherapy is essential in attenuating cardiovascular risk and improving metabolic outcomes in RTA individuals [27-30].

Neurological and Cognitive Effects

Renal tubular acidosis (RTA) manifests with notable neurological complications, encompassing cognitive impairment and peripheral neuropathy. Chronic acidosis disrupts cerebral function, leading to cognitive deficits such as impaired attention, memory dysfunction, and decreased executive function in RTA individuals. Moreover, acidemia exacerbates peripheral neuropathy, characterized by sensory disturbances, motor weakness, and neuropathic pain, further compromising the quality of life in affected patients. The neurological manifestations of RTA underscore the systemic impact of acid-base disturbances, necessitating comprehensive evaluation and management strategies to mitigate cognitive and peripheral nerve dysfunction [31-34]. The neurologic dysfunction observed in RTA arises from multifaceted mechanisms, including alterations in neurotransmitter metabolism, neuronal excitability, and cerebral blood flow regulation. Acidosis disrupts neurotransmitter synthesis and release, impairing synaptic transmission, and neuronal signaling in the central nervous system. Additionally, acidemia potentiates

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751

neuronal hyperexcitability and neuroinflammation, contributing to neuronal injury and dysfunction. Furthermore, acidosis alters cerebral blood flow dynamics, compromising oxygen delivery and metabolic substrate utilization in the brain, further exacerbating neurologic impairment in RTA individuals. To assess and manage neurological complications in RTA, comprehensive neurocognitive evaluation, including neuropsychological testing and nerve conduction studies, is essential to delineate the extent of neurologic dysfunction and guide targeted therapeutic interventions to optimize cognitive and peripheral nerve function [32-34].

Quality of Life and Psychosocial Considerations

Renal tubular acidosis (RTA) and its systemic manifestations significantly impact patients' quality of life, posing multifaceted challenges beyond physiological symptoms. The complex interplay between acid-base disturbances and extrarenal manifestations of RTA, including cardiovascular complications, neurological dysfunction, and metabolic derangements, collectively undermine patients' well-being and functional capacity. Chronic symptoms such as fatigue, musculoskeletal pain, and cognitive impairment impose substantial physical and psychological burdens on individuals with RTA, impairing their ability to engage in daily activities and social interactions. Furthermore, the unpredictable nature of RTA exacerbates emotional distress and anxiety, leading to heightened psychological morbidity and reduced overall quality of life for affected patients. Psychosocial factors are pivotal in influencing adherence to treatment and disease management in RTA individuals. Patient education and empowerment are crucial in fostering self-management skills, promoting treatment adherence, enhancing disease control, and optimizing health outcomes. Additionally, addressing psychosocial needs through multidisciplinary care teams, including psychologists, social workers, and support groups, facilitates holistic patient-centered care, providing emotional support and coping strategies for individuals living with RTA. Moreover, cultivating a supportive environment within healthcare settings and community networks fosters resilience and empowerment, empowering RTA patients to navigate the challenges of their condition and improve their overall well-being [35-38].

Future Directions: Integrating Systemic Perspectives into RTA Management

Recognizing and addressing the systemic implications of renal tubular acidosis (RTA) is paramount in optimizing patient care and outcomes. Moving beyond the traditional nephron-centric approach, integrating systemic perspectives into RTA management entails interdisciplinary collaboration and personalized medicine approaches. By incorporating insights from diverse specialties, including nephrology, endocrinology, cardiology, and neurology, tailored therapeutic strategies can be developed to mitigate renal and extrarenal manifestations of RTA, thereby improving overall patient well-being. Furthermore, future research endeavors should focus on elucidating the intricate interplay between acid-base disturbances and systemic organ systems, exploring novel biomarkers, and developing targeted interventions to ameliorate the systemic burden of RTA and enhance patient care.

Conclusion

Renal tubular acidosis (RTA) presents a complex clinical landscape, extending far beyond its traditional characterization as a renal disorder. As evidenced by the intricate interplay between acid-base disturbances and various organ systems, RTA's systemic implications underscore the necessity for a comprehensive, interdisciplinary approach to patient care. By integrating insights from nephrology, endocrinology, cardiology, neurology, and other specialties, personalized medicine strategies can be tailored to address renal and extrarenal manifestations of RTA, thereby optimizing patient outcomes. Moreover, ongoing research endeavors aimed at elucidating the systemic impact of RTA and developing innovative therapeutic modalities hold promise for advancing our understanding and managing this intricate disorder, ultimately enhancing patient care and well-being.

References

1. Batlle D, Haque SK (2012) Genetic Causes and Mechanisms of Distal Renal Tubular Acidosis. Nephrol Dial Transplant 27(10): 3691-704.
2. Wagner CA, Mohebbi N (2010) Urinary pH and Stone Formation. J Nephrol 23(Suppl16): S165-S169.
3. Rodriguez Soriano J (2002) Renal Tubular Acidosis: The Clinical Entity. J Am Soc Nephrol 13(8): 2160-2170.
4. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL (2019) Brenner and Rector's The Kidney. 11th ed. Philadelphia, PA: Elsevier.
5. Palmer Biff F, Kelepouris Ellie, Clegg Deborah J (2020) Renal Tubular Acidosis and Management Strategies: A Narrative Review. Adis J 38: 949-968.
6. Yaxley J, Pirrone C (2016) Review of the Diagnostic Evaluation of Renal Tubular Acidosis. Ochsner J Winter 16(4): 525-530.
7. Celotto AC, Capellini VK, Baldo CF, Dalio MB, Rodrigues AJ, et al. (2008) Effects of acid-base imbalance on vascular reactivity. Brazil J Med and Biol Res 41(6): 439-445.
8. Ruffin VA, Salameh AI, Boron WF, Parker MD (2014) Intracellular pH regulation by acid-base transporters in mammalian neurons. Front Physiol 5: 43.
9. Hamm L Lee, Nazih Nakhoul, Kathleen S, Hering-Smith (2015) Acid-base homeostasis. Clin J Am Soc Nephrol 10(12): 2232-2242.
10. Hopkins E, Terrence S, and Sandeep S (2018) Physiology, acid base balance.
11. Reddi, Alluru S (2020) Acid-Base Disorders. Springer International Publishing.
12. Both Tim, Robert Z, Ewout JH, Martin Van HP, Virgil ASH Dalm, et al. (2014) Everything you need to know about distal renal tubular acidosis in autoimmune disease. Rheumatology Int 34(8): 1037-1045.

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751

13. Morris CR, Sebastian A (2002) Alkali therapy in renal tubular acidosis: Who needs it? J Am Society Nephrol 13(8): 2186-2188.

14. Guo W, Ji P, Xie Y (2023) Genetic diagnosis and treatment of inherited renal tubular acidosis. Kidney Dis (Basel) 9(5): 371-383.

15. Krieger NS, Frick KK, Bushinsky DA (2004) Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13(4): 423-36.

16. Trepiccione F, Walsh SB, Ariceta G, Boyer O, Emma F, et al. (2021) Distal renal tubular acidosis: Erknet/ESPN clinical practice points. Nephrol Dial Transplant 36(9): 1585-1596.

17. Magni G, Unwin RJ, Moochhala SH (2021) Renal tubular acidosis (RTA) and kidney stones: Diagnosis and management. Arch Esp Urol 74(1): 123-128.

18. Mustaqeem R, Arif A (2023) Renal Tubular Acidosis. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

19. Chukwuedozie VC, Garg T, Chaudhry HA, Shawl SH, Mishra P, et al. (2022) Late-Onset Hypokalemic Periodic Paralysis in an Adult Female with Type 2 Renal Tubular Acidosis: A Case Report. Cureus 14(8): e27695.

20. Cohen JD, Blumenthal R, Horn HR, Weintraub H, Weglicki W (2002) Torsades de Pointes, a potential complication of diuretic-induced hypokalemia and hypomagnesemia in patients with congestive heart failure: Conference presentation of a Generic patient. Curr Therap Res 63(12): 803-809.

21. Palmer BF, Kelepouris E, Clegg DJ (2021) Renal Tubular Acidosis and Management Strategies: A Narrative Review. Adv Ther 38(2): 949-968.

22. James H, Sondheimer M (2024) Hyporeninemic Hypoaldosteronism treatment & management. Approach Considerations, Pharmacologic Therapy, Consultations.

23. Kraut JA, Madias NE (2016) Metabolic Acidosis of CKD: An Update. Am J Kidney Dis 67(2): 307-317.

24. Kovesdy CP, Anderson JE, Kalantar-Zadeh K (2005) Association of Acidosis with Cardiovascular Disease Risk Factors in Chronic Kidney Disease. Kidney Int 67(6): 2587-92.

25. Kusumoto FM, Goldschlager N (2009) Cardiac Arrhythmias. Med Clin North Am 93(5): 1021-1051.

26. Navaneethan SD, Shao J, Buysse J, Bushinsky DA (2019) Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 14(7): 1011-1020.

27. Moe OW, Fuster D (2019) Clinical Acid-Base Disorders: Mechanisms and Consequences. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, editors. Brenner and Rector's The Kidney. 11th ed. Philadelphia, PA: Elsevier p. 833-872.

28. Kraut JA, Madias NE (2016) Metabolic Acidosis of CKD: An Update. Am J Kidney Dis 67(2): 307-317.

29. Wesson DE, Simoni J (2010) Acid Retention during Kidney Failure Induces Endothelin and Aldosterone Production Which Lead to Progressive GFR Decline, a Situation Amplified by Dietary Acid Load. Kidney Int 78(11): 1128-1135.

30. Frassetto L, Sebastian A (1996) Age and Systemic Acid-Base Equilibrium: Analysis of Published Data. J Gerontol Biol Sci Med Sci 51(1): B91-B99.

31. Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, et al. (2013) Electrolyte Disorders in Community Subjects: Prevalence and Risk Factors. Am J Med 126(3): 256-263.

32. Adrogué HJ, Madias NE (1998) Management of Life-Threatening Acid-Base Disorders. N Engl J Med 338(1): 26-34.

33. Wiederkehr MR, Kalogiros J, Krapf R (2016) Correction of Metabolic Acidosis Improves Insulin Resistance in Chronic Kidney Disease. BMC Nephrol 17(1): 158.

34. Pacheco G, Beker BM, Atlante A, Bobadilla NA (2010) Extracellular Acidosis-Induced Neuronal Death and Genomic Analysis of NMDA Receptor-independent Mechanisms. PLOS One 5(7): e11756.

35. Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, et al. (2014) Identification of Risk Factors for Elevated Transaminases in Methotrexate Users Through an Electronic Health Record. Arthritis Care Res (Hoboken) 66(8): 1159-1166.

36. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, et al. (2009) Dose-Related Patterns of Glucocorticoid-Induced Side Effects. Ann Rheum Dis 68(7): 1119-1124.

37. Cohen S, Kamarck T, Mermelstein R (1983) A Global Measure of Perceived Stress. J Health Soc Behav 24(4): 385-396.

38. Alok R, Das SK, Agarwal GG, Salwahan L, Srivastava R (2011) Relationship of Severity of Depression, Anxiety and Stress with Severity of Fibromyalgia. Clin Exp Rheumatol 29(6 Suppl 69): S70-S72.

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751

DOI: 10.19080/JOJUN.2024.09.555751

How to cite this article: José C R C, Tania E S, Alba Vidal R, Carlos E D O, Nune A D, et al. Beyond the Nephron: Exploring Systemic Implications of Renal Tubular Acidosis. JOJ Urology & Nephrology, 2024; 9(1): 555751. DOI: 10.19080/JOJUN.2024.09.555751